Market capitalization | $85.52b |
Enterprise Value | $104.57b |
PER (TTM) P/E ratio | 191.36 |
EV/FCF (TTM) EV/FCF | 13.24 |
EV/Sales (TTM) EV/Sales | 3.81 |
P/S ratio (TTM) P/S ratio | 3.12 |
P/B ratio (TTM) P/B ratio | 4.88 |
Dividend yield | 4.37% |
Last dividend (FY23) | $3.00 |
Activate alerts on the share price, dividend yield, valuation (e.g. P/E ratio or EV/sales) or strategy scores and sit back and relax.
32 Analysts have issued a Gilead Sciences forecast:
32 Analysts have issued a Gilead Sciences forecast:
Mar '24 |
+/-
%
|
||
Turnover | 27,417 27,417 |
2%
2%
|
|
Gross income | 21,298 21,298 |
2%
2%
|
|
EBITDA | 12,075 12,075 |
5%
5%
|
EBIT (operating result) EBIT | 9,332 9,332 |
11%
11%
|
Net profit | 484 484 |
91%
91%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.
Head office | United States |
CEO | Daniel O'Day |
Employees | 18,000 |
Founded | 1987 |
Website | www.gilead.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.